German Researchers Detail Efficacy of AMDL's DR-70 Cancer Test as Tumor Marker for Ovarian Carcinoma
February 27 2006 - 5:00AM
PR Newswire (US)
TUSTIN, Calif., Feb. 27 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), developer and marketer of tests for the early detection
of cancer and other serious diseases, today announced that
researchers from Johannes Gotenberg University, Germany, tested the
diagnostic validity of the Company's DR-70(R) cancer test kit
compared to CA-125, the standard test, as a tumor marker for the
detection of ovarian carcinoma. The researchers simultaneously
investigated the serum activities of the two tests with 61
preoperative patients with histologically confirmed ovarian
carcinoma and one hundred healthy people. The specificity for
DR-70(R) in the test was 100 percent (determining the presence of
cancer) and sensitivity (determining the type of cancer) was 83.6
percent, 13.1 percent higher than the CA-125 test. The German
researchers concluded that "DR-70(R) represents a tumor marker with
which ovarian carcinoma can be diagnosed at levels of sensitivity
and specificity which compare favorably to those measured with
CA-125." The study is published in the German Journal of Obstetrics
and Gynecology. The researchers in the paper write that the
DR-70(R) immunoassay quantifies the amount of fibrin degradation
products in the body, which is produced from malignant cells.
DR-70(R) "has successfully been used for the detection of a number
of cancers including lung, stomach, breast, rectum, liver, colon
and uterus cancer," the German researchers said. Gary Dreher, AMDL
CEO, said the Company is pleased with the research. He emphasized
that AMDL's primary objective remains receiving U.S. Food &
Drug Administration clearance to market DR-70(R), which would
simultaneously increase market awareness and acceptance in the
international marketplace. About AMDL AMDL, Inc. (AMEX:ADL),
headquartered in Tustin, California, is a theranostics company,
involved in the detection and treatment of the same disease,
cancer. AMDL is the inventor, developer and worldwide marketer
through exclusive distribution agreements of the DR-70(R)
non-invasive cancer blood test, which has demonstrated its ability
to detect the presence in humans of up to 13 cancers 84 percent of
the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdl.com/. Forward-Looking Statements We intend that the
statements in this press release that are not historical constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended and Section 21 of the
Securities Exchange Act of 1934, as amended and are subject to
numerous risks and uncertainties, including the risks (i) that the
transaction described may not be completed when expected, or at
all, (ii) the risk that the terms of the definitive acquisition
agreements may materially differ from that disclosed herein, (iii)
the risks related to the inability to obtain or meet conditions
imposed for, governmental and other approvals of the transaction,
including the approval by the stockholders of AMDL, (iv) risks
related to the uncertainty surrounding the transaction and
transactions of this type and (v) the costs related thereto. In
addition, these forward-looking statements are subject to the other
risks of AMDL's business, including, but not limited to, (a) AMDL's
failure to complete successfully the development of new or enhanced
products, (b) AMDL's future capital needs, (c) the lack of market
demand for any new or enhanced products that AMDL may develop, (d)
the lack of market acceptance of AMDL's products and its limited
revenues to date, (e) the success of competitive products, other
economic factors affecting AMDL and its markets, and (f) other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release in the event of new circumstances or unanticipated events
that may occur in the future. Contact: AMDL, Inc. Gary L. Dreher
President & CEO (714) 505-4460 First Call Analyst: FCMN
Contact: DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Oct 2023 to Oct 2024